Top 10 Life Science Startup Investors in Hong Kong in April 2025

Last updated: Apr 2025 A list of 10 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Hong kong. We rank investors based on the number of investments they made in Life science companies from Hong kong. We update this investor list every month.

Top 10 Life Science Startup Investors in Hong Kong in April 2025

Investor	Life Science Hong Kong investments
Alibaba Entrepreneurs Fund	2
Alon Capital Ltd	1
Prox Ventures	1
Hillhouse Investment	1
Tiger Jade Capital	1
Proxima Ventures Ltd	1
AEF Greater Bay Area Fund	1
Vectr	1
Hillhouse Ventures	1
Gobi Partners	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

The Entrepreneurs Fund is a not-for-profit initiative launched by Alibaba Group in 2015 to help entrepreneurs and young graduates realize their dreams and vision. Two separate funds have been set up in Hong Kong and Taiwan respectively to support specific programs in each place.

Investment focus

Software, E-Commerce, Artificial Intelligence
Series A, Seed, Series B
Hong Kong, Taiwan, United States

Portfolio highlights

Ziwu Technology — Ziwu Technology offers the conversion of bio-based waste into sustainable new materials and provides environmentally friendly solutions.
Rice Robotics Limited — The friendliest robot at your service.
BioMed Technology Holdings — BioMed offer a comprehensive service that includes a range of sophisticated tests performed by professionals, together with an interpretation and recommendations for how to live a healthy life.

Make the right startup move by using our startup tools, guides, calculators and templates. Learn from other successful entrepreneurs by reading our case studies

Investment focus

Biopharma, Life Science, Biotechnology
Series A
Hong Kong

Portfolio highlights

Great Bay Bio — Great Bay Bio Ltd. is a high-tech company that develops blue ocean biopharmaceuticals with a digital platform. It has a long history of biomedical research and development and rich experience in product development. Adhering to the national strategic concept of scientific and technological innovation and coordinated development of the Greater BayArea, Dawan Biotechnology brings together high-quality resources from Europe, the United States, Singapore, and Hong Kong to build a biopharmaceutical development platform centered on AI technology, big data, and Internet of Things technology, which greatly shortens The drug development cycle significantly reduces development costs and has great industry competitive advantages.

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Investment focus

Medical, Biotechnology, Health Care
Seed, Funding Round, Series A
China, United States, United Kingdom

Portfolio highlights

Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
Cytonus Therapeutics — Cytonus Therapeutics is a biotech company that develops a therapeutic platform designed to treat immune-related disorders. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads.
Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Series C
China, United States, Singapore

Portfolio highlights

dinii — Dinii is a mobile order platform for take-out shops.
Ascentium — At Ascentium, we believe in the power of partnership to realise unlimited growth potential.
Xingmai Innovation — Xingmai Innovation creates, develops, and sells intelligent swimming pool cleaning robots.

Tiger Jade Capital is a Private Equity fund focused on global healthcare industry. It is a comprehensive healthcare fund covering new drugs, CRO, medical equipment, etc.

Investment focus

Biopharma, Life Science, Biotechnology
Series A
Hong Kong

Portfolio highlights

Great Bay Bio — Great Bay Bio Ltd. is a high-tech company that develops blue ocean biopharmaceuticals with a digital platform. It has a long history of biomedical research and development and rich experience in product development. Adhering to the national strategic concept of scientific and technological innovation and coordinated development of the Greater BayArea, Dawan Biotechnology brings together high-quality resources from Europe, the United States, Singapore, and Hong Kong to build a biopharmaceutical development platform centered on AI technology, big data, and Internet of Things technology, which greatly shortens The drug development cycle significantly reduces development costs and has great industry competitive advantages.

Proxima Ventures is focused on the management of investment portfolios for its customers. It offers them with financial products and consulting services. Proxima Ventures was acquired by Soluto in October 2013. Proxima Ventures was founded by Chaim Venezia and Uri Ra'anan and is based in Tel Aviv, Israel.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
China, United States, Israel

Portfolio highlights

VerImmune — Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors.
Yidianling — Yidianling is a psychological counselling platform that provides free mental health services such as free questions and answers, psychological tests, expert services, and training lectures.
Immune-Onc Therapeutics — Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.

AEF Greater Bay Area Fund is an investment fund.

Investment focus

Biotechnology, Sports, Sustainability
Seed, Series A, Series B
Hong Kong, China, Macao

Portfolio highlights

ORCA-TECH — ORCA-TECH is a manufacturer of self-driving boat.
SleekFlow — SleekFlow makes customer messaging apps such as WhatsApp and Facebook connected to one platform for teams to better support and engage customers.
Scolioscan — Scolioscan focuses on medical imaging technology research & development, self-service production and technology distribution and promotion.

Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.

Investment focus

FinTech, Financial Services, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, Hong Kong, Singapore

Portfolio highlights

Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.

Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.

Investment focus

Manufacturing, Biotechnology, Health Care
Series A, Series B, Seed
China, Singapore, Norway

Portfolio highlights

Metanovas Biotech — Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning.
LiNeng Times — LiNeng Times is a technology company that involves in the production, sales & services of the core components of X-ray imaging systems.
kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.

Gobi Partners is the most interconnected Pan-Asian venture capital firm with US$1.5 billion in assets under management (AUM). Headquartered in Kuala Lumpur and Hong Kong, the firm supports entrepreneurs from the early to growth stages and focuses on emerging and underserved markets.Founded in 2002, Gobi has raised 15 funds to date, invested inover 350 startups and nurtured 10 unicorns. Gobi has grown to 15 locations across key markets in Bangkok, Beijing, Cairo, Guangzhou, Ho Chi Minh City, Hong Kong, Jakarta, Karachi, Kuala Lumpur, Lahore, Manila, Shanghai, Shenzhen, Singapore and Surabaya.As a Participant of the United Nations Global Compact, Gobi Partners is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption to ensure long-term value creation and sustainability across our portfolio.